CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
复制标题
DOI：
10.1016/j.jalz.2018.01.010
复制
发表时间：
2018-11
期刊：
影响因子：
--
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Hansson O;Seibyl J;Stomrud E;Zetterberg H;Trojanowski JQ;Bittner T;Lifke V;Corradini V;Eichenlaub U;Batrla R;Buck K;Zink K;Rabe C;Blennow K;Shaw LM;Swedish BioFINDER study group;Alzheimer's Disease Neuroimaging Initiative
我们研究了全自动Elecsys脑脊液（CSF）免疫测定结果是否与正电子发射断层扫描（PET）一致，并能预测临床进展，即便采用在独立队列中确定的临界值也是如此。
针对瑞典BioFINDER研究中的[18F]氟美他莫PET确定了Elecsys淀粉样蛋白-β1 - 42（Aβ）、总tau/Aβ(1 - 42)以及磷酸化tau/Aβ(1 - 42)的临界值（n = 277），并在阿尔茨海默病神经影像学倡议（ADNI）中针对[18F]氟贝他吡PET进行了验证（n = 646）。还对轻度认知障碍患者（n = 619）的临床进展进行了研究。
在BioFINDER研究中，脑脊液总tau/Aβ(1 - 42)和磷酸化tau/Aβ(1 - 42)的比值与PET分类高度一致（总体一致率：90%；曲线下面积：94%）。通过预先设定的临界值确定的脑脊液生物标志物状态在阿尔茨海默病神经影像学倡议中与PET分类高度一致（总体一致率：89% - 90%；曲线下面积：96%），并且预测了轻度认知障碍患者2年内更大程度的临床衰退。令人惊讶的是，tau/Aβ比值在预测基于视觉判读的结果方面与半定量PET图像评估一样准确。
Elecsys脑脊液生物标志物检测可能为阿尔茨海默病诊断提供可靠的PET替代方法。
We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. Cutoffs for Elecsys amyloid-β1–42 (Aβ), total tau/Aβ(1–42), and phosphorylated tau/Aβ(1–42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer’s Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. CSF total tau/Aβ(1–42) and phosphorylated tau/Aβ(1–42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer’s Disease Neuroimaging Initiative (overall percent agreement: 89%–90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read–based outcomes. Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer’s disease diagnosis.
登录
查看更多内容
影响因子：
5.3
作者：
Janelidze S;Zetterberg H;Mattsson N;Palmqvist S;Vanderstichele H;Lindberg O;van Westen D;Stomrud E;Minthon L;Blennow K;Swedish BioFINDER study group;Hansson O
通讯作者：
Hansson O
DOI：
10.1016/j.jalz.2011.03.005
发表时间：
2011-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
通讯作者：
Phelps CH
影响因子：
--
作者：
Bjerke, Maria;Portelius, Erik;Blennow, Kaj
通讯作者：
Blennow, Kaj
DOI：
10.1016/j.jalz.2015.05.001
发表时间：
2015-07
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Jagust WJ;Landau SM;Koeppe RA;Reiman EM;Chen K;Mathis CA;Price JC;Foster NL;Wang AY
通讯作者：
Wang AY
影响因子：
4.2
作者：
Mattsson, Niklas;Lonneborg, Anders;Hansson, Oskar
通讯作者：
Hansson, Oskar